Prof. Nathan Cherny, Director of our Pain and Palliative Medicine Unit in our Oncology Institute and our Norman Levan Chair of Humanistic Medicine was the lead author of the updated version of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) published this month in the Annals of Oncology.
Since 2016, this scale is used to grade all new medications or indications of anti-neoplastic treatments in solid tumors approved by the European Medicines Agency and presenting these scores in relevant ESMO Clinical Practice Guidelines or as an ‘eUpdate’.
Prof. Cherny, said: “The ESMO-MCBS has shown itself to be a valued tool for evaluating the magnitude of benefit from clinical studies…. The ESMO-MCBS is an evolving project. We are constantly evaluating the validity and reasonableness of the scoring generated by the ESMO-MCBS, looking to identify and understand problems and seeking ways to improve the scale…”
Please read this article for more information.